Neovascular (wet) age-related macular degeneration is an advanced AMD form characterized by pathologic choroidal neovascularization with leakage under the retina, causing rapid central vision loss.
The FDA approved updated labeling for Vabysmo to allow extended treatment of macular edema following retinal vein occlusion beyond six months. The label update removes the prior 6-month restriction and retains monthly 6 mg intravitreal dosing.
The FDA approved an updated Vabysmo label for macular edema following retinal vein occlusion beyond six months. The decision extends treatment based on data showing visual acuity gains and central subfield thickness reductions maintained through week 72.
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
The FDA has approved an expanded label for Sandoz's aflibercept biosimilar Enzeevu to include multiple retinal indications beyond its original approval for neovascular age-related macular degeneration. The product is expected to launch in the US in Q4 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07587515 |
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration |
RECRUITING | PHASE1/PHASE2 |
| NCT07567898 |
Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates |
NOT_YET_RECRUITING | NA |
| NCT07557121 |
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration |
NOT_YET_RECRUITING | PHASE2 |
| NCT07501052 |
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07484074 |
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 |
COMPLETED | PHASE1 |
| NCT07390253 |
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration |
ACTIVE_NOT_RECRUITING | |
| NCT07328776 |
AI vs. Physician for Anti-VEGF Decision-Making: An RCT |
NOT_YET_RECRUITING | NA |
| NCT06759597 |
The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration |
NOT_YET_RECRUITING | |
| NCT06717139 |
Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD |
ACTIVE_NOT_RECRUITING | |
| NCT06346600 |
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD |
RECRUITING |
